97 results on '"Sakanoue I"'
Search Results
2. Impact of Donor Age on Survival of Lung Transplant Recipients According to Their Primary Diagnosis
- Author
-
Tantawi, A.A., primary, Itoda, Y., additional, Ayyat, K., additional, Okamoto, T., additional, Thuita, L., additional, Sakanoue, I., additional, Elgharably, H., additional, Yun, J., additional, and McCurry, K., additional
- Published
- 2023
- Full Text
- View/download PDF
3. Expert consensus on perioperative treatment for non-small cell lung cancer
- Author
-
Duan, J, Tan, F, Bi, N, Chen, C, Chen, K-N, Cheng, Y, Chu, Q, Ge, D, Hu, J, Huang, Y, Jiang, T, Long, H, Lu, Y, Shi, M, Wang, J, Wang, Q, Yang, F, Yang, N, Yao, Y, Ying, J, Zhou, C, Zhou, Q, Bongiolatti, S, Brunelli, A, Fiorelli, A, Gobbini, E, Gridelli, C, John, T, Kim, JJ, Lin, SH, Metro, G, Minervini, F, Novoa, NM, Owen, DH, Rodriguez, M, Sakanoue, I, Scarci, M, Suda, K, Tabbo, F, Tam, TCC, Tsuchida, M, Uchino, J, Voltolini, L, Gao, S, Duan, J, Tan, F, Bi, N, Chen, C, Chen, K-N, Cheng, Y, Chu, Q, Ge, D, Hu, J, Huang, Y, Jiang, T, Long, H, Lu, Y, Shi, M, Wang, J, Wang, Q, Yang, F, Yang, N, Yao, Y, Ying, J, Zhou, C, Zhou, Q, Bongiolatti, S, Brunelli, A, Fiorelli, A, Gobbini, E, Gridelli, C, John, T, Kim, JJ, Lin, SH, Metro, G, Minervini, F, Novoa, NM, Owen, DH, Rodriguez, M, Sakanoue, I, Scarci, M, Suda, K, Tabbo, F, Tam, TCC, Tsuchida, M, Uchino, J, Voltolini, L, and Gao, S
- Published
- 2022
4. Real-Time Lung Weight Measurement to Assess Pulmonary Function During Cellular Ex Vivo Lung Perfusion
- Author
-
Kosaka, R., primary, Sakota, D., additional, Niikawa, H., additional, Ohuchi, K., additional, Arai, H., additional, Sakanoue, I., additional, McCurry, K.R., additional, and Okamoto, T., additional
- Published
- 2022
- Full Text
- View/download PDF
5. Left Ventricular Assist Device Mode: Co-Pulse Left Ventricular Unloading in Working Mode of Ex Vivo Heart Perfusion
- Author
-
Sakota, D., primary, Kosaka, R., additional, Nagaoka, E., additional, Ohuchi, K., additional, Tahara, T., additional, Arai, H., additional, Sakanoue, I., additional, McCurry, K.R., additional, and Okamoto, T., additional
- Published
- 2022
- Full Text
- View/download PDF
6. Mechanical Circulatory Support During Lung Transplantation: Choices, Outcomes and Impact of Duration
- Author
-
Ayyat, K.S., primary, Weingarten, N., additional, Okamoto, T., additional, Sakanoue, I., additional, Ahmad, U., additional, Unai, S., additional, Yun, J.J., additional, Budev, M., additional, Elgharably, H., additional, and McCurry, K.R., additional
- Published
- 2022
- Full Text
- View/download PDF
7. Ex-Vivo Pulmonary Artery Angioscopy: A Novel Technique for Management of Donor Lung Pulmonary Embolism
- Author
-
Ayyat, K.S., primary, Okamoto, T., additional, Sakanoue, I., additional, Elgharably, H., additional, Ahmad, U., additional, Unai, S., additional, Yun, J.J., additional, Budev, M., additional, and McCurry, K.R., additional
- Published
- 2022
- Full Text
- View/download PDF
8. Sequential Ex Vivo Lung Perfusion for Prolonged Lung Preservation: Does the Second EVLP Reset the Lung Conditions?
- Author
-
Sakanoue, I., primary, Okamoto, T., additional, Ayyat, K.S., additional, Yun, J.J., additional, Fujioka, H., additional, Farver, C.F., additional, Date, H., additional, and McCurry, K.R., additional
- Published
- 2022
- Full Text
- View/download PDF
9. The Complete Score for Comprehensive Evaluation of Donor Lungs in Ex-Vivo Lung Perfusion: An Approach for Optimizing the Outcomes of Transplantation
- Author
-
Ayyat, K.S., primary, Okamoto, T., additional, Sakanoue, I., additional, Elgharably, H., additional, Ahmad, U., additional, Unai, S., additional, Yun, J.J., additional, Budev, M., additional, and McCurry, K.R., additional
- Published
- 2022
- Full Text
- View/download PDF
10. Pulmonary Dead Space Fraction: A Predictive Factor for Transplant Suitability in Clinical Ex Vivo Lung Perfusion
- Author
-
Sakanoue, I., primary, Okamoto, T., additional, Ayyat, K.S., additional, Yun, J.J., additional, Elgharably, H., additional, Unai, S., additional, Ahmad, U., additional, Budev, M.M., additional, and McCurry, K.R., additional
- Published
- 2022
- Full Text
- View/download PDF
11. The Complete Score for Assessment of Donor Lungs: A Comprehensive Evaluation System in Clinical Ex-Vivo Lung Perfusion
- Author
-
Ayyat, K.S., primary, Okamoto, T., additional, Sakanoue, I., additional, Elgharably, H., additional, Niikawa, H., additional, Said, S.A., additional, Yun, J.J., additional, Nowacki, A.S., additional, and McCurry, K.R., additional
- Published
- 2021
- Full Text
- View/download PDF
12. The Clinical Significance of Donor Lung Weight at Procurement and during Ex Vivo Lung Perfusion
- Author
-
Okamoto, T., primary, Ayyat, K.S., additional, Sakanoue, I., additional, Niikawa, H., additional, Said, S.A., additional, Ahmad, U., additional, Unai, S., additional, Bribriesco, A., additional, Elgharably, H., additional, Yun, J.J., additional, Budev, M., additional, and McCurry, K.R., additional
- Published
- 2021
- Full Text
- View/download PDF
13. Real-Time Lung Weight Measurement during Ex Vivo Lung Perfusion: Clinical Importance of Early Weight Gain
- Author
-
Sakanoue, I., primary, Okamoto, T., additional, Ayyat, K.S., additional, Yun, J.J., additional, Niikawa, H., additional, and McCurry, K.R., additional
- Published
- 2021
- Full Text
- View/download PDF
14. The Evolving Role of Ex Vivo Lung Perfusion during the COVID-19 Pandemic
- Author
-
Ayyat, K.S., primary, Okamoto, T., additional, Sakanoue, I., additional, Elgharably, H., additional, Budev, M.M., additional, Yun, J.J., additional, and McCurry, K.R., additional
- Published
- 2021
- Full Text
- View/download PDF
15. Assessment of Lobar Oxygenation during Ex-Vivo Lung Perfusion May Predict Postoperative Outcomes
- Author
-
Niikawa, H., primary, Okamoto, T., additional, Ayyat, K.S., additional, Sakanoue, I., additional, Yun, J.J., additional, and McCurry, K.R., additional
- Published
- 2021
- Full Text
- View/download PDF
16. Lung Transplantation on Cardiopulmonary Bypass: Time Matters
- Author
-
Ayyat, K.S., primary, Elgharably, H., additional, Okamoto, T., additional, Sakanoue, I., additional, Said, S.A., additional, Yun, J.J., additional, Budev, M.M., additional, Pettersson, G.P., additional, and McCurry, K.R., additional
- Published
- 2021
- Full Text
- View/download PDF
17. (96) Impact of Donor Age on Survival of Lung Transplant Recipients According to Their Primary Diagnosis
- Author
-
Tantawi, A.A., Itoda, Y., Ayyat, K., Okamoto, T., Thuita, L., Sakanoue, I., Elgharably, H., Yun, J., and McCurry, K.
- Published
- 2023
- Full Text
- View/download PDF
18. (67) Screening for Donor Lung Pulmonary Emboli During Ex-Vivo Lung Perfusion
- Author
-
Ayyat, K.S., Okamoto, T., Tantawi, A., Sakanoue, I., Elgharably, H., Ahmad, U., Unai, S., Yun, J., Budev, M., and McCurry, K.
- Published
- 2023
- Full Text
- View/download PDF
19. Single Center Experience of Clinical Ex Vivo Lung Perfusion
- Author
-
Okamoto, T., primary, Sakanoue, I., additional, Ayyat, K.S., additional, Niikawa, H., additional, Ahmad, U., additional, Yun, J.J., additional, Bribriesco, A., additional, Unai, S., additional, Zeeshan, A., additional, Johnston, D., additional, Tong, M., additional, Budev, M., additional, and McCurry, K.R., additional
- Published
- 2020
- Full Text
- View/download PDF
20. Real-Time Lung Weight Measurement: A Simple Predictor for Clinical Outcomes of Ex-Vivo Lung Perfusion
- Author
-
Sakanoue, I., primary, Okamoto, T., additional, Ayyat, K.S., additional, Niikawa, H., additional, Yun, J.J., additional, and McCurry, K.R., additional
- Published
- 2020
- Full Text
- View/download PDF
21. A CLUE for Better Assessment of Donor Lungs: Novel Technique in Clinical Ex-Vivo Lung Perfusion
- Author
-
Ayyat, K.S., primary, Okamoto, T., additional, Niikawa, H., additional, Sakanoue, I., additional, Dugar, S., additional, Latifi, S.Q., additional, Lebovitz, D.J., additional, Moghekar, A., additional, and McCurry, K.R., additional
- Published
- 2020
- Full Text
- View/download PDF
22. The Assessment of Lobe Oxygenation by Differential Blood Gas Analysis on Ex-Vivo Lung Perfusion May Predict Postoperative Outcomes
- Author
-
Niikawa, H., primary, Okamoto, T., additional, Ayyat, K.S., additional, Sakanoue, I., additional, Yun, J.J., additional, and McCurry, K.R., additional
- Published
- 2020
- Full Text
- View/download PDF
23. Lung Transplantation on Cardiopulmonary Bypass: Time Matters
- Author
-
Ayyat, K.S., primary, Elgharably, H., additional, Okamoto, T., additional, Sakanoue, I., additional, Said, S.A., additional, Yun, J.J., additional, Budev, M.M., additional, Pettersson, G., additional, and McCurry, K.R., additional
- Published
- 2020
- Full Text
- View/download PDF
24. The Effect of Blood Transfusion in Lung Donor on the Recipient Survival
- Author
-
Said, S.A.D., primary, Okamoto, T., additional, Nowacki, A.S., additional, Niikawa, H., additional, Ayyat, K., additional, Sakanoue, I., additional, and McCurry, K., additional
- Published
- 2019
- Full Text
- View/download PDF
25. (914) - Comparison of Perioperative Outcomes Between Living-Donor Lobar Lung Transplant Versus Deceased-Donor Lung Transplant.
- Author
-
Sakanoue, I., Nakajima, D., Takahashi, M., Tanaka, S., Yutaka, Y., Ohsumi, A., and Date, H.
- Subjects
- *
LUNG transplantation - Published
- 2024
- Full Text
- View/download PDF
26. Early Weight Gain During Ex Vivo Lung Perfusion Can Predict Transplant Suitability and Post-Transplant Outcomes.
- Author
-
Sakanoue, I., Okamoto, T., Ayyat, K.S., Tantawi, A., Yun, J.J., Niikawa, H., and McCurry, K.R.
- Subjects
- *
WEIGHT gain , *TREATMENT effectiveness , *PERFUSION , *LUNGS , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Real-time lung weight measurement is a simple and non-invasive technique to detect extravascular lung water during ex vivo lung perfusion (EVLP). We aimed to investigate the feasibility of real-time lung weight measurement in clinical EVLP as an early predictor of transplant suitability and post-transplant outcomes. In our clinical acellular EVLP system, real-time lung weight was measured in 117 cases, from 6/2019 to 6/2022. Weights were repeatedly recorded with a scale under the organ chamber throughout the perfusion. Estimated lung weight gain at each time point was calculated by cumulative estimated lung weight up to that time point. According to our recent data on lung weight, 4 categories using adjusted lung weight before starting EVLP (Ad-LW0), Ad-LW0 was calculated as follows: Ad-LW0 [g] = Lung weight before EVLP [g] + (175 - donor height [cm]) × 11.07, Category1: the lowest weight, Category 4: the highest weight). Non-suitable cases (n = 39) had significantly higher estimated lung weight gain than suitable cases (n = 78) throughout the perfusion (Figure A). Estimated lung weight gain at 10 mins and 60 mins were significantly higher in non-suitable cases in each Ad-LW0 category (Figure B, C). Specifically, the area under the receiver-operating characteristic curve to identify transplant non-suitability in category 4 was 0.81 for estimated lung weight gain at 10 mins (cut-off value: -43.6 g) and 0.89 for 60 mins (cut-off value: -1.3 g). In transplanted cases, estimated lung weight gain at 60 min was significantly higher in PGD 2-3 cases (n = 16) than PGD 0-1 cases (n = 58) (1.3 ± 53.0 vs -42.9 ± 52.1 [g], p < 0.05) with 4 ungradable cases. Early weight gain during EVLP using real-time lung weight measurement can predict transplant suitability and post-transplant outcomes. Abnormal value of real-time lung weight data has a specific role as an early alarm for any potential evidence of poor lung function during evaluation and post-transplant period. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Impact of Ex Vivo Lung Perfusion on a Lung Transplant Program: A Single Center Experience.
- Author
-
Okamoto, T., Ayyat, K., Sakanoue, I., Tantawi, A., Unai, S., Ahmad, U., Elgharably, H., Yun, J., Budev, M., and McCurry, K.
- Subjects
- *
LUNG transplantation , *LUNG volume , *PERFUSION , *LUNGS , *TREATMENT effectiveness - Abstract
Ex vivo lung perfusion (EVLP) is a useful tool to evaluate marginal lungs. The aim of this study is to investigate if EVLP expands donor pool and improves clinical outcomes of lung transplantation. From Jan 2014 to Dec 2021, 868 lung transplants were performed at Cleveland Clinic. Of these, EVLP were used in 105 cases (12%). Toronto-type EVLP program was initiated on Feb 2016. Donor indication for EVLP included 1) marginal lungs, 2) extended DCD (agonal time > 60 min), 3) logistics, and 4) 3rd party procurement. EVLP evaluation was performed using standard parameters, ultrasound, and lung weight measurement. COMPLETE score and donor lung weight category protocols were initiated on 2019 and 2020, respectively. Endpoints included Primary graft dysfunction, hospital stay, and 1 year survival. Study cohort was divided into 4 periods; 2014-2015, 2016-2017, 2018-2019, and 2020-2021 by years. Average lung transplant volume was higher in 2nd-4th period than in 1st period (233 vs. 198 LTx). Total EVLP volume (Recovery rate) was 157 (67%). EVLP case increased; 0 in 2014-2015, 9 (77%) in 2016-2017, 58 (64%) in 2018-2019, and 90 (68%) in 2020-2021. EVLP indications included marginal lungs (79%), extended DCD (10%), logistics (15%), and 3rd party procurement (7%). Primary graft dysfunction Grade 3 at 72 hour during 2nd-4th periods was 13% in EVLP group and 10% in Straight lung transplant group (p = 0.16): The value of both groups decrease to 6.5% in EVLP and 6.0% in straight lung transplant group in 2020-2021 (Figure). There was no significant difference in hospital stay and 1 year survival between the two groups in 2nd-4th periods (hospital stay; 24 and 21 days, 1 year survival; 89 vs. 87%, respectively). These data suggest that EVLP might be useful to increase lung transplant volume and to improve clinical outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. Back-Table Evaluation Prior to Ex-Vivo Lung Perfusion: An Approach for Improving Utilization Rates.
- Author
-
Ayyat, K.S., Okamoto, T., Tantawi, A., Sakanoue, I., Elgharably, H., Ahmad, U., Unai, S., Yun, J., Budev, M., and McCurry, K.
- Subjects
- *
PERFUSION , *LUNGS , *LUNG transplantation - Abstract
Ex-vivo lung perfusion (EVLP) technology plays a pivotal role in expanding the donor pool. However, its expensive costs remain a hurdle, especially for cases ending up non-suitable for transplant. Therefore, maintaining acceptable utilization rates (transplantable / total EVLP cases) is an important goal for EVLP programs. In this study, we tested back-table evaluation tools prior to EVLP that can help in identifying non-recoverable donor lungs to avoid the additional costs of perfusing non-transplantable lungs. Marginal donor lungs and lungs procured by other teams were evaluated at back-table to decide whether it could be transplanted directly, needed further evaluation by EVLP, or declined before EVLP. The back-table evaluation included lung weight (LW) measurement, direCt Lung Ultrasound Evaluation (CLUE), inspection, and palpation. The LW measurements were adjusted to donor height. The CLUE scores were generated based on edema, atelectasis, and consolidation findings. Out of 109 evaluated donor lungs, 17 were declined before EVLP, 5 were transplanted directly, and 87 were further evaluated by EVLP. Out of the 87 EVLP cases, 56 were transplanted (utilization rate 64.4%). Donor lungs declined before EVLP had significantly higher adjusted LW and CLUE score compared to lungs evaluated by EVLP and transplanted directly (1279 vs 941 vs 833 gm, p < 0.001; 1.4 vs 0.4 vs 0.3, p < 0.001, respectively). The LW measurements of all donor lungs declined before EVLP were above the 80th percentile for donor height and 65 % were above the 90th percentile. On the other hand, the LW of all donor lungs transplanted directly were below the 50th percentile. In the EVLP group, non-suitable donor lungs for transplant had significantly higher adjusted LW and CLUE score compared to suitable donor lungs (1020 vs 925 gm, p = 0.01; 0.47 vs 0.33, p = 0.03, respectively). The area under the receiver-operating characteristic curve to identify donor lungs non-recoverable by EVLP was 0.98 for CLUE and 0.95 for adjusted LW. Our study demonstrated the ability of CLUE and LW measurement to predict the outcome of EVLP and identify non-recoverable donor lungs by EVLP. Thus, utilizing these tools in the back-table evaluation prior to EVLP can help in optimizing the utilization rates by avoiding the perfusion of non-transplantable donor lungs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. Influence of HLA mismatch between donors and recipients on postoperative outcomes in cadaveric lung transplantation.
- Author
-
Kayawake H, Sakanoue I, Tanaka S, Yutaka Y, Nishino Y, Matsumoto A, Ryo T, Matsubara T, Nakajima D, and Date H
- Abstract
Objectives: Generally, HLA matching between donors and recipients is not performed in lung transplantation (LTx). Therefore, whether HLA mismatch between donors and recipients (D/R mismatch) influences postoperative outcomes after LTx remains uncertain. In this study, we investigated the influence of D/R mismatch on postoperative outcomes after cadaveric LTx (CLT)., Methods: A total of 140 CLT procedures were performed between 2012 and 2020. After excluding 5 recipients with preformed DSA and 1 recipient undergoing re-LTx, 134 recipients were enrolled in this retrospective study. The postoperative outcomes were compared between recipients with higher and lower D/R mismatches., Results: The median D/R mismatch (A/B/DR loci) was 4.0 (range, 1-6). When dividing these 134 recipients into two groups (H group [D/R mismatch ≥ 5, n = 57] and L group [D/R mismatch ≤ 4, n = 77]), there were no significant differences in the patient backgrounds. The lengths of hospital and intensive care unit stays were similar (p = 0.215 and p = 0.37, respectively). Although the overall survival was not significantly better in the H group than in the L group (p = 0.062), chronic lung allograft dysfunction-free survival was significantly better in the H group than in the L group (p = 0.027). Conversely, there was no significant difference in the cumulative incidence of de novo donor-specific anti-HLA antibodies (dnDSAs) between the two groups (p = 0.716)., Conclusions: No significant difference in dnDSA development was observed between patients with higher and lower D/R HLA mismatches. Given the favorable outcomes in the high HLA mismatch group, CLTs can be performed safely in recipients with high D/R HLA mismatches., Competing Interests: Declarations. Conflict of interest: None., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
30. Real-time lung weight measurement during clinical ex vivo lung perfusion.
- Author
-
Sakanoue I, Okamoto T, Ayyat KS, Yun JJ, Tantawi AM, and McCurry KR
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Organ Size, Extravascular Lung Water physiology, Retrospective Studies, Organ Preservation methods, Feasibility Studies, Aged, Lung Transplantation, Lung physiopathology, Perfusion methods
- Abstract
Background: Real-time lung weight (LW) measurement is a simple and noninvasive technique for detecting extravascular lung water during ex vivo lung perfusion (EVLP). We investigated the feasibility of real-time LW measurement in clinical EVLP as a predictor of transplant suitability and post-transplant outcomes., Methods: In our clinical acellular EVLP protocol, real-time LW was measured in 117 EVLP cases from June 2019 to June 2022. The estimated LW gain at each time point was calculated using a scale placed under the organ chamber. The lungs were classified into 4 categories based on LW adjusted for height and compared between suitable and unsuitable cases. The relationship between estimated LW gain and primary graft dysfunction was also investigated., Results: The estimated LW gain during the EVLP significantly correlated with the LW gain (post-EVLP LW and pre-EVLP LW) measured on the back table (R
2 = 0.61, p < 0.01). In the adjusted LW categories 2 to 4, the estimated LW gain at 0-1 hour after EVLP was significantly higher in unsuitable cases than in suitable cases. The area under the curve for the estimated LW gain was ≥0.80. Primary graft dysfunction grades 0 to 1 had a significantly lower estimated LW gain at 60 minutes than grades 2 to 3 (-43 vs 1 g, p < 0.01)., Conclusions: Real-time lung measurements can predict transplant suitability and post-transplant outcomes by the early detection of extravascular lung water during the initial 1 hour of EVLP., (Copyright © 2024 International Society for the Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
31. Adult living-donor lobar lung transplant using a small-for-size graft.
- Author
-
Nakajima D, Sakanoue I, Kayawake H, Sumitomo R, Nishikawa S, Tanaka S, Yutaka Y, Menju T, and Date H
- Subjects
- Humans, Male, Female, Adult, Middle Aged, Retrospective Studies, Vital Capacity, Lung surgery, Organ Size, Treatment Outcome, Graft Survival, Aged, Primary Graft Dysfunction etiology, Lung Transplantation methods, Living Donors
- Abstract
Objectives: This study was designed to examine the outcomes of adult living-donor lobar lung transplants (LDLLTs) using small-for-size grafts., Methods: A calculated graft forced vital capacity of <50% of the predicted forced vital capacity of the recipient was considered to indicate a small-for-size graft. Adult recipients (≥18 years) who underwent LDLLTs between 2008 and 2022 were included in this study., Results: We performed 80 adult LDLLTs, using small-for-size grafts in 15 patients and non-small grafts in 65 patients. Grade 3 primary graft dysfunction developed within 72 h after the transplant in 3 patients (20%) in the small group and in 3 patients (4.6%) in the non-small group (P = 0.0763). The 1- and 5-year survival rates were 86.7% and 69.3% in the small group and 93.8% and 77.1% in the non-small group (P = 0.742). In the small group, the native lungs were spared in 8 patients, whereas 2 lobar grafts were implanted with non-spared native lungs in the other 7 patients. The 1- and 5-year survival rates were significantly better in the spared group (both 100%) than in the non-spared group (71.4% and 23.8%; P = 0.0375). The spared group showed a significantly higher median percent forced vital capacity after the transplant than the non-spared group (68.5% vs 44.9%; P = 0.0027)., Conclusions: Although the use of small-for-size grafts was associated with a higher rate of severe primary graft dysfunction, no differences were found in survival rates. When the graft is small, the native lung should be partially spared if possible., (© The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Pulmonary Metastasectomy after Immune Checkpoint Inhibitors in Renal Cell Carcinoma.
- Author
-
Sakanoue I, Hamaji M, Nakajima D, and Date H
- Abstract
The management of oligometastatic renal cell carcinoma with pulmonary metastases is controversial and occasionally requires multimodality management, including salvage pulmonary metastasectomy after immune checkpoint inhibitors (ICIs). However, limited data are available on these patients. We describe a case series of three consecutive patients who underwent salvage pulmonary metastasectomy after ICIs for oligometastatic renal cell carcinoma and discussed the important characteristics of these patients. After salvage pulmonary metastasectomy, none of the patients had recurrent pulmonary metastases, although one of them developed a brain metastasis postoperatively. Our case series suggests that salvage pulmonary metastasectomy after ICIs may control pulmonary metastases in carefully selected patients with oligometastatic renal cell carcinoma, although the management of extrapulmonary metastases may be required after salvage pulmonary metastasectomy., Competing Interests: None declared., (Thieme. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
33. Pulmonary metastasectomy after immune checkpoint inhibitors in malignant melanoma.
- Author
-
Sakanoue I, Hamaji M, Ohsumi A, Nakajima D, and Date H
- Subjects
- Humans, Skin Neoplasms pathology, Skin Neoplasms surgery, Skin Neoplasms secondary, Skin Neoplasms drug therapy, Treatment Outcome, Immune Checkpoint Inhibitors therapeutic use, Immune Checkpoint Inhibitors adverse effects, Lung Neoplasms secondary, Lung Neoplasms surgery, Lung Neoplasms drug therapy, Melanoma secondary, Melanoma surgery, Melanoma drug therapy, Metastasectomy adverse effects, Pneumonectomy adverse effects
- Abstract
The management of malignant melanoma with pulmonary metastases is controversial and occasionally requires multimodality management, including pulmonary metastasectomy after immune checkpoint inhibitors (ICIs). However, limited data are available on these patients. We described a case series of three consecutive patients who underwent pulmonary metastasectomy after ICIs for malignant melanoma and discussed the important characteristics of these patients. After pulmonary metastasectomy, none of the patients had recurrent pulmonary metastases, although extrapulmonary metastases were developed. Our case series suggests that pulmonary metastasectomy after ICIs may control pulmonary metastases in carefully selected patients with malignant melanoma., Competing Interests: Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
34. Pneumocephalus resulting from traumatic pneumothorax and brachial plexus avulsion.
- Author
-
Date N, Hamakawa H, Sakanoue I, Saito T, and Takahashi Y
- Abstract
Background: Traumatic pneumocephalus is commonly encountered after basal skull fractures and rarely associated with blunt chest trauma. Here, we report a case of pneumocephalus caused by traumatic pneumothorax and brachial plexus avulsion., Case Presentation: A 20-year-old male was admitted to our hospital following a motorcycle accident with complete paralysis of the right upper limb. 2 days later, follow-up computed tomography revealed a slight right pneumothorax, pneumomediastinum around the neck, and intracranial air without skull fracture. Air migrates into the subarachnoid space through a dural tear caused by a brachial plexus avulsion. The pneumocephalus immediately improved after the insertion of a chest drain., Conclusion: Pneumothorax combined with brachial plexus avulsion could lead to pneumocephalus. Immediate chest drainage might be the best way to stop the migration of air; however, care should be taken to not worsen cerebrospinal fluid leakage., Competing Interests: The authors declare no conflicts of interest., (© 2024 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine.)
- Published
- 2024
- Full Text
- View/download PDF
35. Intermittent Ex Vivo Lung Perfusion in a Porcine Model for Prolonged Lung Preservation.
- Author
-
Sakanoue I, Okamoto T, Ayyat KS, Yun JJ, Farver CF, Fujioka H, Date H, and McCurry KR
- Subjects
- Swine, Animals, Lung, Perfusion adverse effects, Perfusion methods, Cytokines, Adenosine Triphosphate, Organ Preservation methods, Lung Transplantation adverse effects, Lung Transplantation methods
- Abstract
Background: Ex vivo lung perfusion expands the lung transplant donor pool and extends preservation time beyond cold static preservation. We hypothesized that repeated regular ex vivo lung perfusion would better maintain lung grafts., Methods: Ten pig lungs were randomized into 2 groups. The control underwent 16 h of cold ischemic time and 2 h of cellular ex vivo lung perfusion. The intermittent ex vivo lung perfusion group underwent cold ischemic time for 4 h, ex vivo lung perfusion (first) for 2 h, cold ischemic time for 10 h, and 2 h of ex vivo lung perfusion (second). Lungs were assessed, and transplant suitability was determined after 2 h of ex vivo lung perfusion., Results: The second ex vivo lung perfusion was significantly associated with better oxygenation, limited extravascular water, higher adenosine triphosphate, reduced intraalveolar edema, and well-preserved mitochondria compared with the control, despite proinflammatory cytokine elevation. No significant difference was observed in the first and second perfusion regarding oxygenation and adenosine triphosphate, whereas the second was associated with lower dynamic compliance and higher extravascular lung water than the first. Transplant suitability was 100% for the first and 60% for the second ex vivo lung perfusion, and 0% for the control., Conclusions: The second ex vivo lung perfusion had a slight deterioration in graft function compared to the first. Intermittent ex vivo lung perfusion created a better condition for lung grafts than cold static preservation, despite cytokine elevation. These results suggested that intermittent ex vivo lung perfusion may help prolong lung preservation., Competing Interests: I.S. was supported by a fellowship grant from the Uehara Memorial Foundation (Tokyo, Japan). K.R.M. is a consultant for Abiomed Inc (Danvers, MA). The other authors declare no conflicts of interest., (Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
36. Left ventricular assist device mode: Co-pulse left ventricular unloading in a working mode of ex vivo heart perfusion.
- Author
-
Sakota D, Kosaka R, Nagaoka E, Ohuchi K, Tahara T, Arai H, Sakanoue I, McCurry KR, and Okamoto T
- Subjects
- Swine, Animals, Heart Ventricles, Ventricular Function, Left, Heart, Perfusion, Heart-Assist Devices, Heart Failure
- Abstract
Background: For normothermic ex vivo heart perfusion (EVHP), a resting mode and working mode have been proposed. We newly developed a left ventricular assist device (LVAD) mode that supports heart contraction by co-pulse synchronized LVAD., Methods: Following resting mode during time 0 to 1 hour, pig hearts (n = 18) were perfused in either resting, working, or LVAD mode during time 1 to 5 hour, and then myocardial function was evaluated in working mode at 6 hour. The preservation ratio was defined as the myocardial mechanical function at 330 minute divided by the function at 75 minute. In LVAD mode, LVAD unloaded the pressure and the volume in the left ventricle in the systolic phase., Results: The LVAD group was significantly associated with higher preservation ratios in cardiac output (resting, 33 ± 3; working, 35 ± 5; LVAD, 76% ± 5%; p < 0.001), stroke work, dP/dt maximum, and dP/dt minimum compared with the other groups. Glucose consumption was significantly reduced in the resting group. The LVAD group was significantly associated with higher myocardial oxygen consumption (resting, 2.2 ± 0.3; working; 4.6 ± 0.5; LVAD, 6.1 ± 0.5 mL O
2 /min/100 g, p < 0.001) and higher adenosine triphosphate (ATP) levels (resting, 1.1 ± 0.1; working, 0.7 ± 0.1; LVAD, 1.6 ± 0.2 μmol/g, p = 0.001) compared with the others., Conclusion: These data suggest that myocardial mechanical function was better preserved in LVAD mode than in resting and working modes. Although our data suggested similar glycolysis activity in the LVAD and working groups, the higher final ATP in the LVAD group might be explained by reduced external work in LVAD., (Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF
37. Real-time Lung Weight Measurement During Cellular Ex Vivo Lung Perfusion: An Early Predictor of Transplant Suitability.
- Author
-
Kosaka R, Sakota D, Sakanoue I, Niikawa H, Ohuchi K, Arai H, McCurry KR, and Okamoto T
- Subjects
- Animals, Extracorporeal Circulation methods, Ischemia, Lung, Perfusion methods, Swine, Lung Transplantation methods
- Abstract
Background: Increased extravascular lung water during ex vivo lung perfusion (EVLP) is associated with ischemia reperfusion injury and poor pulmonary function. A non-invasive technique for evaluating extravascular lung water during EVLP is desired to assess the transplant suitability of lungs. We investigated real-time lung weight measurements as a reliable method for assessing pulmonary functions in cellular EVLP using a porcine lung model., Methods: Fifteen pigs were randomly divided into 3 groups: control (no warm ischemia) or donation after circulatory death groups with 60 or 90 min of warm ischemia (n = 5, each). Real-time lung weight gain was measured by load cells positioned at the bottom of the organ chamber., Results: Real-time lung weight gain at 2 h was significantly correlated with lung weight gain as measured on a back table ( R = 0.979, P < 0.01). Lung weight gain in non-suitable cases (n = 6) was significantly higher than in suitable cases (n = 9) at 40 min (51.6 ± 46.0 versus -8.8 ± 25.7 g; P < 0.01, cutoff = +12 g, area under the curve = 0.907). Lung weight gain at 40 min was significantly correlated with PaO 2 /FiO 2 , peak inspiratory pressure, shunt ratio, wet/dry ratio, and transplant suitability at 2 h ( P < 0.05, each). In non-suitable cases, lung weight gain at 66% and 100% of cardiac output was significantly higher than at 33% ( P < 0.05)., Conclusions: Real-time lung weight measurement could potentially be an early predictor of pulmonary function in cellular EVLP., Competing Interests: The authors declare no conflicts of interest., (Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc.)
- Published
- 2023
- Full Text
- View/download PDF
38. Prone ex vivo lung perfusion protects human lungs from reperfusion injury.
- Author
-
Niikawa H, Okamoto T, Ayyat KS, Itoda Y, Sakanoue I, Farver CF, Yun JJ, and McCurry KR
- Subjects
- Animals, Humans, Lung, Oxygen, Perfusion, Swine, Lung Transplantation adverse effects, Reperfusion Injury etiology, Reperfusion Injury prevention & control, Reperfusion Injury pathology
- Abstract
Background: We previously reported beneficial effects of prone positioning during ex vivo lung perfusion (EVLP) using porcine lungs. In this study, we sought to determine if prone positioning during EVLP was beneficial in human donor lungs rejected for clinical use., Methods: Human double lung blocs were randomized to prone EVLP (n = 5) or supine EVLP (n = 5). Following 16 h of cold storage at 4°C and 2 h of cellular EVLP in either the prone or supine position. Lung function, compliance, and weight were evaluated and transplant suitability determined after 2 h of EVLP., Results: Human lungs treated with prone EVLP had significantly higher partial pressure of oxygen/fraction of inspired oxygen (P/F) ratio [348 (291-402) vs. 199 (191-257) mm Hg, p = 0.022] and significantly lower lung weight [926(864-1078) vs. 1277(1029-1483) g, p = 0.037] after EVLP. 3/5 cases in the prone group were judged suitable for transplant after EVLP, while 0/5 cases in the supine group were suitable. When function of upper vs. lower lobes was evaluated, prone EVLP lungs showed similar P/F ratios and inflammatory cytokine levels in lower vs. upper lobes. In contrast, supine EVLP lungs showed significantly lower P/F ratios [68(59-150) vs. 467(407-515) mm Hg, p = 0.012] and higher tissue tumor necrosis factor alpha levels [100.5 (46.9-108.3) vs. 39.9 (17.0-61.0) ng/ml, p = 0.036] in lower vs. upper lobes., Conclusions: Prone lung positioning during EVLP may optimize the outcome of EVLP in human donor lungs, possibly by improving lower lobe function., (© 2022 International Center for Artificial Organ and Transplantation (ICAOT) and Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
39. Expert consensus on perioperative treatment for non-small cell lung cancer.
- Author
-
Duan J, Tan F, Bi N, Chen C, Chen KN, Cheng Y, Chu Q, Ge D, Hu J, Huang Y, Jiang T, Long H, Lu Y, Shi M, Wang J, Wang Q, Yang F, Yang N, Yao Y, Ying J, Zhou C, Zhou Q, Zhou Q, Bongiolatti S, Brunelli A, Fiorelli A, Gobbini E, Gridelli C, John T, Kim JJ, Lin SH, Metro G, Minervini F, Novoa NM, Owen DH, Rodriguez M, Sakanoue I, Scarci M, Suda K, Tabbò F, Tam TCC, Tsuchida M, Uchino J, Voltolini L, Wang J, and Gao S
- Abstract
Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-527/coif). CZ serves as an Editor-in-Chief of Translational Lung Cancer Research from August 2014 to July 2022. SHL serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023. GM serves as an unpaid editorial board member of Translational Lung Cancer Research from February 2016 to July 2023. CG serves as an unpaid editorial board member of Translational Lung Cancer Research from September 2019 to September 2023, and received honoraria as speaker bureau or advisory board member or consulting fees form Menarini, Roche, Eli Lilly, Boehringer, Amgen, Pfizer, Novartis, MSD, BMS, Astra Zeneca, Takeda, Novartis, GSK, Karyopharm. Qing Z received lecture and presentations fees from AstraZeneca, Boehringer Ingelheim, BMS, Eli Lilly, MSD, Pfizer, Roche, and Sanofi. AB received consulting fees as an Advisory Board with Astra Zeneca, BD, Ethicon, Medtronic, Roche, and is the president of European Society of Thoracic Surgeons. TJ received consulting fees from Roche, Merck, MSD, Puma, AstraZeneca, BMS, Amgen, Gilead, Specialised Therapeutics. DHO reports research funding (to institution) from Genentech, BMS, Merck, Pfizer, Palobiofarma, and Onc. AI. MR received honoraria for lectures and expert meetings from Astrazeneca, and also received honoraria for lectures and expert meetings as well as travel expenses from Abex. KS received a research grant from Boehringer-Ingelheim, through Kindai University Faculty of Medicine, has received consulting fees from AstraZeneca, and has received honoraria from Chugai, Taiho, and AstraZeneca. FT received speaker bureau from AstraZeneca. The other authors have no conflicts of interest to declare.
- Published
- 2022
- Full Text
- View/download PDF
40. Clinical significance of donor lung weight at procurement and during ex vivo lung perfusion.
- Author
-
Okamoto T, Ayyat KS, Sakanoue I, Niikawa H, Said SA, Ahmad U, Unai S, Bribriesco A, Elgharably H, Budev MM, Yun JJ, and McCurry KR
- Subjects
- Humans, Lung, Perfusion, Retrospective Studies, Tissue Donors, Lung Transplantation, Primary Graft Dysfunction epidemiology
- Abstract
Background: Elevated donor lung weight may adversely affect donor lung transplant suitability and post-transplant outcomes. The objective of this study is to investigate the impact of lung weight after procurement and ex vivo lung perfusion (EVLP) on transplant suitability, post-transplant graft dysfunction, and clinical outcomes and define the donor lung weight range most relevant to clinical outcomes., Methods: From February 2016 to August 2020, 365 human lung donors to a single transplant center were retrospectively reviewed. 239 were transplanted without EVLP, 74 treated with EVLP (50 went on to transplant), and 52 declined for transplant without EVLP consideration. Donor lung weights were measured immediately after procurement and, when performed, after EVLP. Lung weights were adjusted by donor height and divided into 4 quartiles., Results: Donor lungs in the highest weight quartile at donor hospital had a significantly lower transplant suitability rate after EVLP, higher rates of primary graft dysfunction grade 3 at 72 hours, and longer intensive care unit/hospital stay. For lungs treated with lung perfusion, the highest lung weight quartile at the end of lung perfusion was associated with a significantly lower transplant suitability rate, higher incidence of primary graft dysfunction grade 3 at 72 hours, and longer intensive care unit/hospital stay, compared to the other categories., Conclusions: Donor lung weight stratified by quartile categories can assist decision-making regarding need for EVLP at the donor hospital as well as during EVLP evaluation. Caution should be used when considering donor lungs in the highest weight quartile for transplantation., (Copyright © 2022 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
41. The Effect of Blood Transfusion in Lung Donors on Recipient Survival.
- Author
-
Said SA, Okamoto T, Nowacki AS, Niikawa H, Ayyat KS, Sakanoue I, Yun JJ, and McCurry KR
- Subjects
- Adult, Cause of Death, Female, Graft Survival, Humans, Kaplan-Meier Estimate, Male, Models, Statistical, Risk Factors, Blood Transfusion, Lung Transplantation mortality, Tissue Donors, Transplant Recipients statistics & numerical data
- Abstract
Background: Blood transfusion can have detrimental effects on the pulmonary system, leading to lung injury and respiratory decompensation with subsequent increased morbidity and mortality in surgical and critically ill patients. How much of this effect is carried from a lung donor to transplant recipient is not fully understood, raising questions regarding transplant suitability of lungs from transfused donors., Methods: United Network for Organ Sharing data were reviewed. Lung transplants from adult donors and known donor transfusion status were included; multiorgan transplants and retransplants were excluded. Recipient mortality was evaluated based on donor and recipient characteristics using a Kaplan-Meier survival estimate, Cox proportional hazards, and logistic regression models. We further assessed whether recipient mortality risk modified the donor transfusion effect., Results: From March 1996 to June 2017, 20,294 transplants were identified. Outcome analysis based on transfusion status showed nonsignificant difference in 1-year mortality (P = .214). Ninety-day recipient mortality was significantly higher with transfusion of >10 units (U) vs 1-10 U or no transfusion (8.5%, 6.1%, and 6.0%, respectively, P = .005). Multivariable analysis showed increased 90-day mortality with transfusion of >10 U compared to no transfusion (odds ratio 1.62, P < .001), whereas 1-10 U showed no difference (odds ratio 1.07, P = .390). When stratified by recipient transplant risk, transfusion of >10 U was associated with increased mortality even with the lowest-risk recipients, while transfusion of 1-10 U showed no mortality increase even in the highest-risk recipients., Conclusions: Donor transfusion of >10 U of blood was associated with increased 90-day recipient mortality even in low-risk transplants. This risk should be considered when evaluating donor lungs., (Copyright © 2021 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
42. Successful Lung Transplantation After Acellular Ex Vivo Lung Perfusion With Prone Positioning.
- Author
-
Niikawa H, Okamoto T, Ayyat KS, Sakanoue I, Yun JJ, and McCurry KR
- Subjects
- Humans, Male, Middle Aged, Prone Position, Treatment Outcome, Young Adult, Lung physiology, Lung surgery, Lung Transplantation methods, Perfusion methods, Preoperative Care methods
- Abstract
Use of prone positioning during ex vivo lung perfusion (EVLP) with the Toronto protocol reduced pulmonary edema in marginal human donor lungs. This report describes 2 cases in which prone positioning during EVLP significantly reduced lung weight. One of the 2 cases resulted in successful double-lung transplantation., (Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
43. Lung Transplant for Patient With Idiopathic Pneumonia Syndrome.
- Author
-
Said SA, Okamoto T, Sakanoue I, Unai S, Budev M, Akindipe O, and McCurry KR
- Subjects
- Adult, Female, Humans, Remission Induction, Syndrome, Hematopoietic Stem Cell Transplantation adverse effects, Lung Transplantation, Pneumonia etiology, Pneumonia surgery, Postoperative Complications etiology, Postoperative Complications surgery
- Abstract
Idiopathic pneumonia syndrome (IPS) is a serious complication after hematopoietic stem cell transplantation. Despite the high mortality rate with medical management, there have been no reported cases of lung transplants for patients with IPS. We report a case involving a 44-year-old woman who developed IPS 5 months after hematopoietic stem cell transplantation for myelodysplastic syndrome. Despite aggressive medical management, the patient required intubation and was administered extracorporeal membrane oxygenation while awaiting recovery. However, her condition continued to deteriorate, and she subsequently underwent a double lung transplant with uneventful recovery. With the high mortality of medically managed IPS, lung transplant could prove to be lifesaving., (Copyright © 2020 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
44. Cellular Ex Vivo Lung Perfusion Beyond 1 Hour May Improve Marginal Donor Lung Assessment.
- Author
-
Niikawa H, Okamoto T, Ayyat KS, Itoda Y, Sakanoue I, Farver CF, Yun JJ, and McCurry KR
- Subjects
- Adult, Bronchoscopy, Donor Selection standards, Female, Humans, Lung diagnostic imaging, Male, Middle Aged, Pulmonary Gas Exchange physiology, Time Factors, Transplants diagnostic imaging, Donor Selection methods, Lung physiology, Lung Transplantation standards, Perfusion, Transplants physiology
- Abstract
Background: Ex vivo lung perfusion (EVLP) permits extended evaluation of donor lungs for transplant. However, the optimal EVLP duration of Lund protocol is unclear. Using human lungs rejected for clinical transplant, we sought to compare the results of 1 versus 2 h of EVLP using the Lund protocol., Methods: Twenty-five pairs of human lungs rejected for clinical transplant were perfused with the Lund EVLP protocol. Blood gas analysis, lung compliance, bronchoscopy assessment, and perfusate cytokine analysis were performed at both 1 and 2 h. Recruitment was performed at both time points. Donor lung transplant suitability was determined at both time points., Results: All cases were divided into four groups based on transplant suitability assessment at 1 h and 2 h of EVLP. In group A (n = 10), lungs were judged suitable for transplant at both 1 and 2 h of EVLP. In group B (n = 6), lungs were suitable at 1 h but nonsuitable at 2 h. In group C (n = 2), lungs were nonsuitable at 1 h but suitable at 2 h. Finally, in group D (n = 7), lungs were nonsuitable for transplant at both time points. In both groups B and C (n = 8), the transplant suitability assessment changed between 1 and 2 h of EVLP., Conclusions: In human lungs rejected for transplant, transplant suitability differed at 1 versus 2 h of EVLP in 32% of lungs studied. Evaluation of lungs with Lund protocol EVLP beyond 1 h may improve donor organ assessment., (Copyright © 2019 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
45. Large traumatic pneumatocele treated using video-assisted thoracoscopic surgery.
- Author
-
Shishido Y, Minami K, Sakanoue I, Takahashi Y, and Hamakawa H
- Subjects
- Adult, Humans, Male, Treatment Outcome, Lung Diseases surgery, Lung Injury complications, Pneumonectomy methods, Thoracic Injuries complications, Thoracic Surgery, Video-Assisted
- Published
- 2019
- Full Text
- View/download PDF
46. Association Between Formalin Fixation Time and Programmed Cell Death Ligand 1 Expression in Patients With Non-Small Cell Lung Cancer.
- Author
-
Kawachi H, Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, and Tomii K
- Subjects
- Aged, Female, Formaldehyde chemistry, Gene Expression Regulation, Neoplastic, Humans, Immunohistochemistry, Male, Neoplasm Staging, Tissue Fixation, B7-H1 Antigen genetics, Biomarkers, Tumor genetics, Carcinoma, Non-Small-Cell Lung genetics, Carcinoma, Non-Small-Cell Lung pathology
- Abstract
Background/aim: The expression of programmed cell death ligand 1 (PD-L1) determined by immunohistochemistry (IHC) may be associated with tissue formalin fixation time in non-small cell lung cancer (NSCLC) samples. We investigated the association between the PD-L1 expression and formalin fixation time, and clarified the optimal duration of fixation for accurate PD-L1 evaluation., Materials and Methods: We collected 55 tumor specimens from resected NSCLC patients. The samples were halved and immediately fixed in 10% buffered formalin for 12-24 h (normal fixation), or 96-120 h (prolonged fixation). Each specimen was stained using two assay systems (22C3 and SP263) for PD-L1., Results: The mean PD-L1 tumor proportion score was not significantly different between normal and prolonged fixation groups for either 22C3 or SP263 (normal fixation: 18.8%; prolonged fixation: 16.3%, p=0.277; normal fixation: 16.2%; prolonged fixation: 17.6%, p=0.560, respectively)., Conclusion: Formalin fixation duration for up to 120 h does not affect PD-L1 IHC expression. PD-L1 tumor proportion score of tumor specimens can be evaluated by IHC even if these have been fixed in formalin outside the recommended duration in clinical practice., (Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
47. Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263.
- Author
-
Fujimoto D, Yamashita D, Fukuoka J, Kitamura Y, Hosoya K, Kawachi H, Sato Y, Nagata K, Nakagawa A, Tachikawa R, Date N, Sakanoue I, Hamakawa H, Takahashi Y, and Tomii K
- Subjects
- Aged, Aged, 80 and over, Antibodies, Monoclonal, Humanized, B7-H1 Antigen metabolism, Biomarkers, Tumor metabolism, Carcinoma, Non-Small-Cell Lung pathology, Cytodiagnosis methods, Female, Humans, Immunohistochemistry, Lung Neoplasms pathology, Male, Middle Aged, B7-H1 Antigen analysis, Carcinoma, Non-Small-Cell Lung metabolism, Early Detection of Cancer methods, Lung Neoplasms metabolism
- Abstract
Background/aim: While the PD-L1 22C3 pharmDx assay is an FDA-approved diagnostic assay for pembrolizumab use, not every pathology laboratory has the Dako Autostainer to use this assay. Since Ventana BenchMark platforms are more common, the Ventana SP263 assay can be used to inform treatment decisions involving nivolumab and pembrolizumab in non-small cell lung cancer (NSCLC). However, some studies have shown discordant results between the two assays. This study aimed was to compare PD-L1 expression using these two assays., Materials and Methods: A total of 100 samples from consecutive cases of resected NSCLC were tested using the two PD-L1 assays., Results: The agreement rates of the two assays were 88-97% at various cut-offs. There was no significant difference between 22C3 and SP263 in tumour proportion score (p=0.455)., Conclusion: The SP263 assay can be used in the place of the 22C3 assay for PD-L1 testing, for guiding therapy with PD-1 axis inhibitors in NSCLC., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
48. Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study.
- Author
-
Fujimoto D, Sato Y, Morimoto T, Uehara K, Ito M, Otsuka K, Nagata K, Sakanoue I, Hamakawa H, Nakagawa A, Takahashi Y, Imai Y, and Tomii K
- Subjects
- Adenocarcinoma drug therapy, Adenocarcinoma pathology, Aged, Antineoplastic Agents, Immunological therapeutic use, B7-H1 Antigen antagonists & inhibitors, Carcinoma, Non-Small-Cell Lung drug therapy, Carcinoma, Non-Small-Cell Lung pathology, Carcinoma, Squamous Cell drug therapy, Carcinoma, Squamous Cell pathology, Case-Control Studies, Female, Follow-Up Studies, Humans, Lung Diseases, Interstitial drug therapy, Lung Diseases, Interstitial pathology, Lung Neoplasms drug therapy, Lung Neoplasms pathology, Male, Prognosis, Stromal Cells metabolism, Stromal Cells pathology, Survival Rate, Adenocarcinoma metabolism, B7-H1 Antigen metabolism, Biomarkers, Tumor metabolism, Carcinoma, Non-Small-Cell Lung metabolism, Carcinoma, Squamous Cell metabolism, Lung Diseases, Interstitial metabolism, Lung Neoplasms metabolism
- Abstract
Background: Programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) checkpoint inhibitors have demonstrated antitumor activity, and immunohistochemical analysis of PD-L1 expression has been used to identify the response in patients with non-small-cell lung cancer (NSCLC). Recently, considerable interest has ensued toward extending the benefit of these inhibitors to high-risk patients, such as those with NSCLC and interstitial lung disease (ILD). However, no studies have compared PD-L1 expression in NSCLC patients with and without ILD. Therefore, we conducted a case-control study to evaluate PD-L1 expression and stromal CD8
+ lymphocyte density in these patients., Materials and Methods: The data from patients with pathologic stage I or II NSCLC who had undergone surgery from January 2007 to January 2016 were analyzed., Results: We identified 62 patients with pathologic stage I or II NSCLC and ILD. We compared these patients with 1:1-matched cohort. In both groups with and without ILD, approximately 60% were PD-L1+ . Tumor cell PD-L1 expression was similar between the groups (median, 1%; interquartile range, 0%-5%; vs. median, 1%; interquartile range, 0%-5%; P = .49). The proportion of patients with positive (≥ 1%) and strongly positive (≥ 50%) PD-L1 expression was also similar between the 2 groups (P = .46 and P = 1.00, respectively). Additionally, the CD8+ lymphocyte density did not differ between patients with and without ILD., Conclusion: PD-L1 expression and stromal CD8+ lymphocyte density were comparable between the NSCLC patients with and without ILD. PD-1 axis inhibitors might be effective for NSCLC patients with ILD., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2018
- Full Text
- View/download PDF
49. Reduced Tumour Proportion Scores for Programmed Cell Death Ligand 1 in Stored Paraffin Tissue Sections.
- Author
-
Sato Y, Fujimoto D, Uehara K, Kawachi H, Nagata K, Nakagawa A, Otsuka K, Sakanoue I, Hamakawa H, Takahashi Y, Imai Y, and Tomii K
- Subjects
- Aged, Aged, 80 and over, Biomarkers, Tumor biosynthesis, Carcinoma, Non-Small-Cell Lung pathology, Humans, Immunohistochemistry methods, Lung Neoplasms pathology, Male, Microtomy, Paraffin Embedding, Pathology, Clinical methods, Retrospective Studies, Time Factors, B7-H1 Antigen biosynthesis, Carcinoma, Non-Small-Cell Lung metabolism, Lung Neoplasms metabolism, Specimen Handling methods
- Abstract
Background/aim: We evaluated the effects of storage of formalin-fixed, paraffin-embedded (FFPE) sections on the tumour proportion score (TPS) for programmed cell death ligand 1 (PD-L1), as indicator in non-small cell lung cancer (NSCLC) tissues of treatment efficacy., Materials and Methods: NSCLC postoperative specimens with PD-L1 TPS ≥50% were obtained and cut into five serial sections. One section was stained immediately, and four were stored at 4°C for 2, 4, 6, or 8 weeks. Slides were subjected to PD-L1 immunohistochemistry using the anti-PD-L1 clone 28-8. PD-L1 TPS were blindly evaluated by two independent pathologists., Results: Twelve specimens (60 slides) were evaluated. After slide storage for 2, 4, 6, and 8 weeks, a TPS of <50% was obtained in five (41%), four (33%), seven (58%), and eight (67%) patients, respectively., Conclusion: TPS values for PD-L1 were reduced by long-term slide storage of FFPE specimens. Sectioned slides should be stained for PD-L1 without delay., (Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
50. Sleeve lobectomy for lung adenocarcinoma treated with neoadjuvant afatinib.
- Author
-
Sakanoue I, Hamakawa H, Kaji R, Imai Y, Katakami N, and Takahashi Y
- Abstract
Afatinib, the second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), has been postulated to be associated with improved inhibition of EGFR-dependent tumor growth compared with first-generation EGFR-TKIs for advanced non-small cell lung cancer (NSCLC). We present a case of lung adenocarcinoma (cT3N0M0) treated with neoadjuvant afatinib and sleeve lobectomy. Because of the location of the tumor, reduced FEV1 value, and the presence of EGFR mutation, the patient was planned to be prescribed afatinib (30 mg daily) for 3 weeks as neoadjuvant therapy and underwent sleeve lobectomy to avoid pneumonectomy as much as possible. Although the patient presented with grade 3 diarrhea and dose reduction of afatinib to 20 mg daily was needed, several image findings showed a partial response of the tumor on Day 20. Oral administration of afatinib was discontinued on Day 22. A right upper sleeve lobectomy combined with partial resection of lower lobe was performed after oral administration of afatinib on Day 24. The patient's postoperative course was uneventful and she has been free of recurrence for 26 months. This strategy could reduce the risk of pneumonectomy with acceptable side effects. The treatment, clinical course and pathological findings of the patient are discussed., Competing Interests: Conflicts of Interest: The authors have no conflicts of interest to declare.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.